e-Edition
Obituaries
Special Sections
Special Occasions
Contact

Subscribe
Paywall Login
Login to Comment
Register

December 11th, 2017

jobs

homes

Home
News
Sports
Business
Entertainment
Classifieds
Commentary

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Dare Bioscience, Inc. - Common Stock (NQ:DARE)

0.8403 -0.0025 (-0.30%)

Delayed Quote Updated: 11:18 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Dare Bioscience, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

December 20, 2023

Via Benzinga

FDA Gives Nod To Daré Bioscience's Trial Of Non-Hormonal Treatment For Dyspareunia, Seeks Additional Funding ↗

December 07, 2023

Daré Bioscience Inc (NASDAQ: DARE) announced that the FDA has cleared its investigational new drug (IND) application for DARE-VVA1 as a non-hormonal treatment option for moderate to severe dyspareunia,...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

December 07, 2023

Via Benzinga

Earnings Outlook For Dare Bioscience ↗

November 08, 2023

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

October 16, 2023

Via Benzinga

Earnings Outlook For Dare Bioscience ↗

August 09, 2023

Via Benzinga

Recap: Dare Bioscience Q1 Earnings ↗

May 11, 2023

Via Benzinga

Earnings Outlook For Dare Bioscience ↗

May 10, 2023

Via Benzinga

Earnings Preview: Dare Bioscience ↗

March 29, 2023

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

September 20, 2023

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

July 31, 2023

On Monday, 27 stocks hit new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

July 21, 2023

On Friday, 54 companies hit new 52-week lows.

Via Benzinga

HC Wainwright & Co. Maintains Buy Rating for Dare Bioscience: Here's What You Need To Know ↗

December 13, 2022

Via Benzinga

Daré Bioscience's Intravaginal Ring Improves Vasomotor, Vaginal Symptoms Of Menopause ↗

October 17, 2022

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

July 17, 2023

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

April 03, 2023

We're starting off the week with a breakdown of the biggest pre-market stock movers worth keeping an eye on Monday morning!

Via InvestorPlace

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

March 02, 2023

Via Benzinga

Daré Bioscience Shares Move Higher Intravaginal Ring Shows Promise In Menopause Symptoms ↗

January 09, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2022 ↗

December 01, 2022

Via Benzinga

Women's Healthcare Company Agile Therapeutics Says It Believes It Has An Effective Business Plan In Place For Growth And Generating Positive Cash Flow ↗

November 14, 2022

Agile Therapeutics Inc. (NASDAQ: AGRX) is on a journey to fulfill the unmet health needs of women with products designed to provide them with contraceptive options.

Via Benzinga

Can This Company’s Birth Control Patch Disrupt The Contraceptive Market?

October 26, 2022

From Evofem Biosciences Inc.’s (OTCMKTS: EVFM) Phexxi vaginal gel contraceptive to Dare Bioscience Inc.’s (NASDAQ: DARE) Ovaprene, an investigational hormone-free monthly intravaginal contraceptive,...

Via TheNewswire.com

Can This Company’s Birth Control Patch Disrupt The Contraceptive Market?

October 26, 2022

By Ernest Dela Aglanu, Benzinga

Via News Direct

Can This Company's Birth Control Patch Disrupt The Contraceptive Market? ↗

October 25, 2022

Via Benzinga

Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful ↗

August 09, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Earnings Outlook For Dare Bioscience ↗

August 08, 2022

Dare Bioscience (NASDAQ:DARE) is set to give its latest quarterly earnings report on Tuesday, 2022-08-09. Here's what investors need to know before the announcement. Analysts estimate that Dare...

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

July 25, 2022

Gainers

Via Benzinga

President Biden Mulls Health Emergency For Abortion Access: Report ↗

July 11, 2022

Via Benzinga

The Daily Biotech Pulse: Pfizer Inks Pact With Africa For COVID-19 Pills, Emergent Bio & Ridgeback To Increase Access To Ebola Treatment, ADC Therapeutics & Sobi In European Pact For Lymphoma Drug ↗

July 08, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

July 07, 2022

Gainers

Via Benzinga

EVFM Stock: Contraception Maker Evofem Biosciences Doubles After Roe Decision ↗

June 27, 2022

Evofem Biosciences is in the spotlight following the overturning of Roe v. Wade. Here's why EVFM stock is a name to watch.

Via InvestorPlace

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

More ways to get to us

Facebook

Twitter

YouTube

ePaper Login
Subscribe
Subscription Services
Archive

About Us

The Lethbridge Herald
Other Publications
Food For Thought

Contact
Careers

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

Advertising
Terms and Conditions & Privacy Policy